IGlar U100

DRUG2 trials

Sponsors

Novo Nordisk A/S, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions

Diabetes Mellitus Type 2Diabetes Mellitus, Type 1Metabolic Dysfunction-Associated Steatotic Liver Disease

Phase 1

A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

CompletedNCT03723772

Novo Nordisk A/SDiabetes Mellitus, Type 1

Start: 2018-11-29End: 2020-06-26Updated: 2025-03-11

Phase 4

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus Combined With Metabolic Dysfunction-associated Steatotic Liver Disease

Enrolling by invitationNCT07274644

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolDiabetes Mellitus Type 2, Metabolic Dysfunction-Associated Steatotic Liver Disease

Start: 2025-03-29End: 2026-06-30Target: 36Updated: 2025-12-10